Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome

Next Previous
Trial Profile

A Phase 1/2, Open-Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Fragile X syndrome; Mental retardation
  • Focus Therapeutic Use
  • Acronyms FAB-C
  • Sponsors Zynerba Pharmaceuticals

Most Recent Events

  • 26 May 2020 New two-year data from open label extension published in the Zynerba pharmaceuticals Media Release.
  • 26 May 2020 According to an Zynerba pharmaceuticals media release, new two-year data from open label extension of this Phase 2 FAB-C Trial in Patients with Fragile X were presented as a poster at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session.
  • 09 Mar 2020 According to a Zynerba pharmaceuticals media release, data will be presented at the American Academy of Neurology (AAN) 2020 Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top